# Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

> **NCT00625651** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 202 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Colon Cancer
- Colorectal Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** AMG 655
- **DRUG:** Modified FOLFOX6
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00625651
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-08
- **Final completion:** 2011-09
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2014-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625651, "Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00625651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*